Compares outpatient and hospital dosing of bispecific antibodies in relapsed myeloma
Studies costs and quality of life of home-style dosing of immunotherapy in relapsed myeloma.
Key facts
- Who runs it
- University Hospital, Toulouse
- Where
- Toulouse, FranceSee the site
- Trial code
- Registry title
- Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 20 Jan 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 2 groups
- Record updated
- 26 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding, who are treated with the bispecific antibody teclistamab, elranatamab or talquetamab.
- Age
- More than 18 years old
- Sex
- All
- Disease stage
- Relapsed and/or refractory multiple myeloma
- Earlier treatment
- Must be treated with teclistamab, elranatamab or talquetamab.
Main reasons for not taking part
- Cannot read or write
- Language barrier
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Relapsed and/or refractory multiple myeloma
- Treated with teclistamab, elranatamab ou talquetamab
- More than 18 years old
- Having received the information from the study and not having objected to participate
- Day hospital care in case of clinical feasibility (good general condition, no rapid progression or major tumor burden, no current infection) and logistics (accommodated less than 30 minutes from the IUCT Oncopole for 48 hours after each dose escalation) or in conventional hospitalization at the IUCT Oncopole
Who cannot take part
- Illiterate subjects or those with a language barrier
Where in France
- CHU de ToulouseToulouse, FranceContact: Aurore PERROT, MD, PhDTaking people
About the trial
What the trial wants to find out
Multiple myeloma is the second most common haematological cancer. Recent innovations have made it possible for relapsed/refractory patients to benefit from the innovative immunotherapy of bispecific antibodies. These antibodies stimulate the immune system to attack tumour cells. The treatment involves an escalating dose of three subcutaneous injections every 2 to 4 days for a total of about 10 days, followed by a weekly treatment phase.
Read full original descriptionShow less
The University Hospital of Toulouse was the first centre in France to offer outpatient dose escalation for this innovative treatment. This form of treatment depends on clinical and logistical feasibility. Where appropriate, patients are treated in a conventional unit. An analysis carried out at Toulouse University Hospital suggests a response to treatment, with no increased risk of complications in the outpatient setting. Patients' quality of life may also be unaffected. In addition, given the increasing demand for care in a context of finite resources, the economic evaluation of healthcare initiatives is becoming essential if we are to maintain a high-quality healthcare system that is accessible to all.
The 2 groups in the trial
- Outpatient step-up dose procedure
Patients treated on an outpatient procedure if it's clinically feasible (good condition general, no rapid progression or major tumor burden, no current infection) and logistics (lived within 30 minutes from the IUCT Oncopole for 48 hours after each step-up dose)
- Conventional procedure
Patients who do not meet the conditions for outpatient care and justify hospitalization in a conventional unit for dose escalation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
- Plain-language title
- Compares outpatient and hospital dosing of bispecific antibodies in relapsed myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 February 2025